P1.102. A Study of Lymph Node Metastasis in cNo.104 Cases of Thoracic Esophageal Squamous Cell Carcinoma

Clicks: 19
ID: 326026
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #242 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Management of Metastatic Cancer Background The JCOG1109 trial established docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy as the standard preoperative treatment for locally advanced thoracic esophageal cancer, achieving improved local control. Subsequently, the JCOG1409 trial demonstrated the non-inferiority of thoracoscopic minimally invasive esophagectomy compared with open surgery, establishing minimally invasive surgery as the standard approach. However, clinical No.104 lymph node metastasis is classified as cM1 disease and is generally considered beyond the standard surgical indication. Consequently, its optimal treatment strategy and oncological outcomes remain controversial. Methods We retrospectively reviewed 58 patients with thoracic esophageal squamous cell carcinoma and clinical No.104 lymph node metastasis (excluding salvage cases) who underwent minimally invasive esophagectomy between January 2018 and February 2023. Results Median age was 68 years; male/female: 49/9; PS 0/1: 44/14; Ut/Mt/Lt: 18/32/8; cT1/2/3/4: 6/1/42/6; cN0/1/2/3: 3/14/25/12.Preoperative chemotherapy was administered in 51 cases (88.0%). R0 resection was achieved in 93.1% of cases, and pNo.104 metastasis was observed in 25cases (43.1%). The 3-year overall survival (OS) rate was 57.5% overall. There was no significant difference in pNo.104R metastasis status (-/+: 44.6%/37.5%; p=0.55), but a significant difference was observed in pNo.104L metastasis status (-/+: 61.5%/44.0%; p=0.04). Similarly, the 2-year RFS was 42.0%. While no significant difference was observed for pNo.104R metastasis-/+: 44.6/37.5% (p=0.55), a significant difference was noted for pNo.104L metastasis-/+: 49.6/0.0% (p=0.003). Conclusion Acceptable oncological outcomes may be achieved in selected patients with clinical No.104 lymph node metastasis undergoing minimally invasive esophagectomy. However, pathological left-sided No.104 metastasis is associated with significantly worse survival and higher recurrence rates, suggesting distinct biological behavior and the potential need for tailored postoperative therapeutic strategies.
Reference Key
openalex_W7203976642 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yusuke Iwabe, Ayumi Nishioka, Daisuke Kajiyama, Yuto Kubo, Kazuma Sato, Mitsumasa Yoshida, Masahiro Yura, Takahiro Kinoshita, Takeo Fujita
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.250
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.250/70761108/doag077.250.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.